The round was led by Golden Ventures, with participation from Hearst Ventures and Argosy Capital, to expand its enterprise BasilIntel SaaS platform, deepen product capabilities, and accelerate the deployment of data-driven insights across the pharma and medical device industry.

本轮融资由 Golden Ventures 领投，Hearst Ventures 和 Argosy Capital 参与，旨在扩展其企业级 BasilIntel SaaS 平台、深化产品能力，并加速在制药和医疗设备行业部署数据驱动的洞察。

Basil Systems delivers an AI-powered SaaS platform transforming how pharma and MedTech companies manage regulatory, clinical, and product lifecycle strategy. By structuring the world's largest indexed database of regulatory, drug, device, and post-market data, Basil helps life sciences organizations accelerate development, reduce risk, and improve product performance.

Basil Systems 提供了一个由人工智能驱动的 SaaS 平台，改变了制药和医疗技术公司管理法规、临床和产品生命周期策略的方式。通过构建全球最大的法规、药物、设备和上市后数据索引数据库，Basil 帮助生命科学组织加速开发、降低风险并提升产品性能。

Trusted by industry leaders, Basil turns complex data into actionable insights that drive better decisions and better patient outcomes..

受到行业领导者的信赖，Basil 将复杂的数据转化为可操作的见解，推动更好的决策和更好的患者结果。